Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader

BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotech company with a market capitalization of $365 million and showing strong momentum with a 13% gain last week, has dosed the first subjects in a Phase 1 study of MRT-8102, a molecular glue degrader targeting NEK7 for inflammatory conditions driven by the NLRP3 inflammasome, the company announced Monday. According to InvestingPro analysis, the company maintains a robust financial position with more cash than debt on its balance sheet.

The randomized, double-blind, placebo-controlled trial in healthy volunteers includes single and multiple ascending dose cohorts designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other pharmacodynamic markers. Initial results are expected in the first half of 2026. With a strong current ratio of 5.61 and liquid assets exceeding short-term obligations, the company appears well-positioned to fund its clinical development programs.

The study also includes a cohort of subjects with increased cardiovascular disease risk and elevated C-reactive protein (CRP) levels, which could provide early insights for potential applications in cardio-immunology indications such as pericarditis and atherosclerotic cardiovascular disease.

"MRT-8102 is the only clinical-stage MGD that selectively targets NEK7, a protein central to NLRP3 inflammasome activation and the downstream dysregulation of IL-1β and IL-6 that underlie multiple inflammatory diseases," said Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics.

According to the company, MRT-8102 has demonstrated potent and selective NEK7 degradation in preclinical studies, including a non-human primate model where it showed near-complete reductions of IL-1β and caspase-1 following ex vivo stimulation of whole blood.

The compound is being developed to potentially address various inflammatory disorders, including cardiovascular disease, gout, osteoarthritis, and neurologic disorders such as Parkinson’s and Alzheimer’s disease.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines using its QuEEN discovery engine. The information in this article is based on a company press release.

In other recent news, Monte Rosa Therapeutics, Inc. has received FDA clearance for an Investigational New Drug (IND) application for MRT-8102, a novel treatment targeting inflammatory diseases. This clearance allows the company to commence a Phase 1 study, with initial results expected in the first half of 2026. Preclinical studies have shown promising results, including significant NEK7 degradation and improvements in inflammatory disease models. Additionally, Monte Rosa has reported breakthrough preclinical results for MRT-51443 in treating HR-positive/HER2-negative breast cancer. This novel treatment, when combined with existing therapies, demonstrated superior tumor regression and potential in delaying resistance to current treatments. The findings are being presented at the American Association for Cancer Research Annual Meeting. Monte Rosa retains full rights to MRT-8102 and is advancing a second-generation NEK7 program. The company also maintains strategic collaborations with Novartis and Roche for developing MGDs for cancer and neurological diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.